Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Serdar Örnek"'
Autor:
Ebru Erdoğan, Koray Yalçın, Cansu Hemşinlioğlu, Aslıhan Sezgin, Utku Seyis, Derya Dilek Kancağı, Cihan Taştan, Bulut Yurtsever, Raife Dilek Turan, Didem Çakırsoy, Selen Abanuz, Gözde Sır Karakuş, Muhammer Elek, Hüseyin Saffet Beköz, Ali İhsan Gemici, Deniz Sargın, Mutlu Arat, Burhan Ferhanoğlu, Ebru Pekgüç, Serdar Örnek, Deram Büyüktaş, Nur Birgen, Siret Ratip, Ercüment Ovalı
Publikováno v:
Turkish Journal of Hematology, Vol 39, Iss 3, Pp 206-210 (2022)
Objective: Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T cell therapies are promising, there are concerns about commercial products regarding their affordability
Externí odkaz:
https://doaj.org/article/556bd673500c45ae8473e751960454e8
Publikováno v:
Turkish Journal of Hematology, Vol 37, Iss 4, Pp 292-294 (2020)
Externí odkaz:
https://doaj.org/article/f0a64cf1c5694302b1a2dfe49f2dd326
Publikováno v:
Turkish Journal of Hematology, Vol 37, Iss 3, Pp 215-216 (2020)
Externí odkaz:
https://doaj.org/article/d479bc6e57fa46e592851764dbe334ee
Autor:
Mutlu Arat, Didem Cakirsoy, Selen Abanuz, Ercument Ovali, Bulut Yurtsever, Ali İhsan Gemici, Utku Seyis, Cansu Hemsinlioglu, Serdar Örnek, Gozde Sir Karakus, Huseyin Saffet Bekoz, Siret Ratip, Ebru Pekguc, Aslıhan Sezgin, Raife Dilek Turan, Koray Yalcin, Deniz Sargin, Muhammer Elek, Cihan Tastan, Deram Buyuktas, Burhan Ferhanoglu, Derya Dilek Kancagi, Nur Birgen, Ebru Erdogan
ObjectiveChimeric antigen receptor T (CAR-T) cell therapies already made an impact on the treatment of B cell malignancies. Although CAR-T cell therapies are promising, there are concerns with commercial products regarding their affordability and sus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::572ac870518042265443af4f71a3838d
https://doi.org/10.1101/2021.09.23.21263731
https://doi.org/10.1101/2021.09.23.21263731
Publikováno v:
Turkish Journal of Hematology
Turkish Journal of Hematology, Vol 37, Iss 3, Pp 215-216 (2020)
Turkish Journal of Hematology, Vol 37, Iss 3, Pp 215-216 (2020)
NA
Publikováno v:
Turkish Journal of Hematology
Turkish Journal of Hematology, Vol 37, Iss 4, Pp 292-294 (2020)
Turkish Journal of Hematology, Vol 37, Iss 4, Pp 292-294 (2020)
NA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ec6248b841eb2c6f0c5048f126da16d
https://doi.org/10.4274/tjh.galenos.2020.2020.0086
https://doi.org/10.4274/tjh.galenos.2020.2020.0086
Autor:
Serdar Örnek
Publikováno v:
Social Sciences Studies Journal. 3:2292-2303
Autor:
Burhan Ferhanoglu, Murat Ozbalak, Okan Falay, Onur Demirkol, Serdar Örnek, Erman Öztürk, Yasemin Bolukbasi, Mustafa Çetiner, Terman Gümüş
Publikováno v:
Leukemialymphoma. 58(5)
Bleomycin is an antineoplastic agent causing fatal pulmonary toxicity. Early diagnosis of bleomycin-induced pneumonitis is crucial to prevent irreversible damage. Pulmonary function tests are unreliable for identifying risk of bleomycin toxicity. Flu
Autor:
Yahya Laleli, Muhlis Cem Ar, Murat Ozbalak, Burhan Ferhanoglu, Tülay Tecimer, Aykut Koroglu, Metin Ozdemirli, Serdar Örnek, Ilyas Tokatlı
Publikováno v:
European journal of haematology. 91(5)
Primary effusion lymphoma (PEL) is a human herpesvirus 8 (HHV8) associated lymphoproliferative disease characterized by effusions in body cavities, and lack of tumor mass. Valganciclovir is a treatment option in PEL, however, little is known about it